Journal of Parenteral and Enteral Nutrition

Volume 18, Issue 1 p. 26-34

Article

Octreotide as an Adjunct to Home Parenteral Nutrition in the Management of Permanent End-Jejunostomy Syndrome

J.D. Stephen,

J.D. Stephen

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

Keefe O' MD, MSC, FRCP,

Keefe O' MD, MSC, FRCP

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

Maren E. Peterson RD,

Maren E. Peterson RD

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

C. Richard Fleming MD,

C. Richard Fleming MD

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

J.D. Stephen,

J.D. Stephen

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

Keefe O' MD, MSC, FRCP,

Keefe O' MD, MSC, FRCP

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

Maren E. Peterson RD,

Maren E. Peterson RD

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

C. Richard Fleming MD,

C. Richard Fleming MD

From the Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, and Jacksonville, Florida

Search for more papers by this author

First published: 01 January 1994

https://doi.org/10.1177/014860719401800101

Citations: 17

Correspondence and reprint requests: Stephen J.D. O'Keefe, MD, GI Clinic, Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa

About

PDF

Tools

Share a link

Email
Facebook
x
LinkedIn
Reddit
Wechat

Abstract

Intravenous fluid requirements for patients with permanent end-jejunostomy syndrome often exceeds 3 L/d, making rehabilitation difficult. The effect of the somatostatin analogue, octreotide (100 μg TID, subcutaneously) in reducing requirements was measured in 10 patients established on home parenteral nutrition. After 10 days of treatment, 72-hour balance measurements demonstrated significant reductions in stomal fluid and electrolyte losses from (mean ± SE) 8.1 ± 1.8 to 4.8 ± 0.7 L/d (p <.03), sodium from 510 ± 71 to 340 ± 41 mEq/d (p <.03), chloride from 533 ± 70 to 315 ± 32 mEq/d (p <.002), and potassium from 101 ± 41 to 79 ± 34 mEq/d (p <.02), permitting an average reduction in intravenous fluid requirements of 1.3 L/d (p <.0003), 118 mEq Na⁺/d (p <.03), 41 mEq K⁺/d (p <.02), and 178 mEq Cl⁻/d (p <.01). This meant that daytime intravenous infusions could be stopped in all patients. Fecal nitrogen losses were decreased (P <.05), but overall there was no significant change in fat and caloric absorption. In addition, hormonal stimulated gastric acid and pancreatic lipase secretions were significantly reduced (p <.05). The effect was most marked in those patients with massive stomal losses and uncontrollable thirst. Continuation of treatment for more than 1 year in 8 of the patients suggested preservation of potency and good tolerance, with the possible exception of accelerated gallstone formation and subacute intestinal obstruction. In conclusion, octreotide has the potential to improve the quality of life of those end-jejunostomy syndrome patients with massive stomal losses, resistant to conventional medical treatment. (Journal of Parenteral and Enteral Nutrition 18:26–36, 1994)

References

1Burnes J U O'Keefe S J D Fleming C R, et al.: Home parenteral nutrition: A 3-year analysis of clinical and laboratory monitoring. JPEN 16: 327–332, 1992.
10.1177/0148607192016004327
CASPubMedWeb of Science®Google Scholar
2Fine K D Krejs G J Fordtran JS: Diarrhoea. IN Gastrointestinal Disease, M H Sleisenger, J S Fordtran (eds). WB Sanders Company, Philadelphia, 1989, pp 290–313.
Google Scholar
3DiCecco S Nelson J Burnes J, et al.: Nutritional intake of gut failure patients on home parenteral nutrition. JPEN 11: 529–532, 1987.
10.1177/0148607187011006529
CASPubMedWeb of Science®Google Scholar
4Messing B Pigot F Rongier M, et al.: Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology 100: 1502–1508, 1991.
10.1016/0016-5085(91)90645-2
CASPubMedWeb of Science®Google Scholar
5Lucey M R Yamada T: Biochemistry and physiology of gastrointestinal somatostatin. Dig Dis Sci 34, 5S–13S, 1989.
10.1007/BF01536041
CASPubMedWeb of Science®Google Scholar
6Cooper J C Williams N S King R F G J, et al.: Effects of long-acting somatostatin analogue in patients with severe ileostomy diarrhea. Br J Surg 73: 128–131, 1986.
10.1002/bjs.1800730219
PubMedWeb of Science®Google Scholar
7Shaffer T J L O'Hanrahan T Rowntree S, et al.: Does somatostatin analogue (SMS 201–995) reduce high output stoma effluent? A controlled trial. Gut 29: A1432–A1433, 1988.
Web of Science®Google Scholar
8Bauer W Briner U Doepfner W, et al.: SMS 201–995 a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140, 1982.
10.1016/0024-3205(82)90087-X
CASPubMedWeb of Science®Google Scholar
9Biovin M Lanspa S J Zinsmeister A R, et al.: Are diets associated with different rates of human interdigestive and post-prandial pancreatic enzyme secretion? Gastroenterology 99: 1763–1771, 1990.
PubMedGoogle Scholar
10Roddy D R Koch T R Reilly W M, et al.: Identification and distribution of immunoreactive peptide YY in the human, canine, and murine gastrointestinal tracts: Species-related antibody recognition differences. Regul Pept 18: 201–212, 1987.
10.1016/0167-0115(87)90008-5
CASPubMedWeb of Science®Google Scholar
11Herbert V Lau K S Gottlieb C W, et al.: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375–1384, 1965.
10.1210/jcem-25-10-1375
CASPubMedWeb of Science®Google Scholar
12Faloona G R Unger R H. Glucagon. IN Methods of Hormone Radioimmunoassay, B M Jaffe, H R Behrman (eds). Academic Press, New York, 1974, pp 317–330.
Google Scholar
13Miller L J Reilly W M Rosenzweig S A, et al.: A soluble interaction between dibutyryl cyclic 3′:5′-monophosphate and cholecystokinin: A possible mechanism for the inhibition of cholecystokinin activity. Gastroenterology 84: 1505–1511, 1983.
CASPubMedWeb of Science®Google Scholar
14Nightingale J M D Walker E R Burnham W R, et al.: Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine. Aliment Pharmacol Ther 3: 367–373, 1989.
10.1111/j.1365-2036.1989.tb00223.x
PubMedWeb of Science®Google Scholar
15Ladefoged K Christensen J C Hegnhoj J, et al.: Effect of a long-acting somatostatin analogue SMS 201–995 on jejunostomy effluents in patients with severe short bowel syndrome. Gut 30: 943–949, 1989.
10.1136/gut.30.7.943
CASPubMedWeb of Science®Google Scholar
16Fordtran J S Locklear TW: Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis 11: 503–521, 1966.
10.1007/BF02233563
CASPubMedWeb of Science®Google Scholar
17Newton C R Govers J J McIntyre P B, et al.: Effect of different drinks on fluid and electrolyte losses from a jejunostomy. J R Soc Med 78: 27–34, 1985.
CASPubMedWeb of Science®Google Scholar
18Woolf G M Miller C Kurian R, et al.: Nutritional absorption in short bowel syndrome: Evaluation of fluid, calorie, and divalent cation requirements. Dig Dis Sci 31: 8–15, 1987.
10.1007/BF01296681
Web of Science®Google Scholar
19McIntyre P B Fitchew M Lennard-Jones J E. Patients with a high jejunostomy do not need a special diet. Gastroenterology 91: 25–33, 1986.
10.1016/0016-5085(86)90434-8
CASPubMedWeb of Science®Google Scholar
20Lembeck B Creutzfeldt W Schleser S, et al.: Effect of the somatostatin analogue sandostatin SMS 201–995 on gastrointestinal, pancreatic, and biliary function and hormone release in normal man. Digestion 36: 108–124, 1987.
10.1159/000199408
PubMedGoogle Scholar
21Williams S T Woltering E A O'Dorisio T M, et al.: Effect of octreotide acetate on pancreatic exocrine function. Am J Surg 157: 459–462, 1989.
10.1016/0002-9610(89)90634-X
PubMedWeb of Science®Google Scholar
22Gyr K E Whitehouse I Beglinger C, et al.: Human pharmacological effects of SMS 201–995 on gastric secretion. Scand J Gastroenterol 21: 96–102, 1986.
10.3109/00365528609087436
Web of Science®Google Scholar
23Loguercio C De Sio I Ramano M, et al.: Effect of somatostatin on salivary secretion in man. Digestion 36: 91–95, 1987.
10.1159/000199405
CASPubMedWeb of Science®Google Scholar
24Kohler E Beglinger C Dettwiler S, et al.: Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas 1: 154–159, 1986.
10.1097/00006676-198603000-00008
PubMedGoogle Scholar
25Rodrigues C A Lennard-Jones J E Thompson D G, et al.: The effects of octreotide, soy polysaccharide, codeine, and loperamide on nutrient, fluid, and electrolyte absorption in the short bowel syndrome. Aliment Pharmacol Ther 3: 159–169, 1989.
10.1111/j.1365-2036.1989.tb00202.x
PubMedWeb of Science®Google Scholar
26Bowyer B A Fleming C R Ludwig J, et al.: Does long-term home parenteral nutrition in adult patients cause chronic liver disease? JPEN 9: 11–17, 1985.
10.1177/014860718500900111
CASPubMedWeb of Science®Google Scholar
27Kvols L K Moertel C G O'Connell M J, et al.: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663–666, 1986.
10.1056/NEJM198609113151102
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume18, Issue1

January 1994

Pages 26-34

Octreotide as an Adjunct to Home Parenteral Nutrition in the Management of Permanent End-Jejunostomy Syndrome

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Octreotide as an Adjunct to Home Parenteral Nutrition in the Management of Permanent End-Jejunostomy Syndrome

Abstract

References

Citing Literature

References

Related

Information